title: Effects of long-term treatment with oxytocin in chronic constipation; a double blind, placebo-controlled pilot trial.
abstract: BACKGROUND
  Oxytocin and its receptor have been found throughout the gastrointestinal (GI) tract, where it affects gut function. Clinically, we have noticed an improvement of bowel habits during lactation in constipated women. The aim of this study was to examine whether oxytocin has an effect on bowel symptoms and psychological well being in women with refractory constipation.
  
  
  METHODS
  Fifty-nine women with refractory constipation were included in a double blind, multicentre study. After a 2-week run-in period, they were randomly allocated to nasal inhalation of either placebo or oxytocin treatment twice daily for 13 weeks, followed by a 2 weeks, posttreatment period. The patients completed a questionnaire every day concerning bowel habits, abdominal pain and discomfort, and Gastrointestinal Symptoms Rating Scale (GSRS) and Psychological General Well-being (PGWB) twice during the study; namely, during the baseline period and at the end of the treatment period.
  
  
  RESULTS
  Both oxytocin and placebo led to improvement of the constipation according to the GSRS and led to improvement in the sensation of incomplete evacuation and anorectal obstruction, without significant differences between the groups. Abdominal pain and discomfort responded weakly to oxytocin, with no effect of the placebo. In a subgroup of patients with IBS and concomitant depression, a weak improvement in depressed mood was observed after oxytocin administartion.
  
  
  CONCLUSIONS
  Nasal administration of oxytocin had no significant advantage over placebo concerning an effect on constipation. However, it seems to have a positive effect on abdominal pain and discomfort and depressed mood. These findings should be further explored.
authors.affiliation: Department of Medicine Malmö University Hospital, Sweden. bodil.ohlsson@kir.lu.se
authors.forename: B
authors.initials: B
authors.lastname: Ohlsson
authors.forename: M
authors.initials: M
authors.lastname: Truedsson
authors.forename: M
authors.initials: M
authors.lastname: Bengtsson
authors.forename: R
authors.initials: R
authors.lastname: Torstenson
authors.forename: K
authors.initials: K
authors.lastname: Sjölund
authors.forename: E S
authors.initials: ES
authors.lastname: Björnsson
authors.forename: M
authors.initials: M
authors.lastname: Simrèn
mesh_terms: D000328:Adult; D000368:Aged; D001007:Anxiety; D002908:Chronic Disease; D003248:Constipation / Q000188:drug therapy* / Q000523:psychology; D003863:Depression; D004311:Double-Blind Method; D005772:Gastrointestinal Transit; D006304:Health Status; D006801:Humans; D008875:Middle Aged; D010121:Oxytocin / Q000627:therapeutic use*; D018579:Patient Selection; D010865:Pilot Projects; D010919:Placebos
chemical_list: D010919:Placebos; D010121:Oxytocin